{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:35:14Z","timestamp":1776065714095,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022030","name":"Silence Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cascade screening can identify individuals with elevated lipoprotein(a) [Lp(a)], a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). The aim of this study is to explore the effectiveness of cascade screening with asymptomatic children as index cases to identify family members with elevated Lp(a).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this retrospective study we used our database consisting of all children referred for a tentative diagnosis of hereditary dyslipidaemia to the Amsterdam University Medical Centers paediatric lipid clinic (1989\u20132023). Elevated Lp(a) was defined as \u226530\u2005mg\/dL or \u226575\u2005nmol\/L. We evaluated two cascade screening approaches (opportunistic and systematic), calculated the number needed to screen (NNS) and repeated the analysis exclusively in children with FH as subgroup with particularly high cardiovascular risk. A total of 1931 children were included (732 indexes, mean age (SD) 11.7 (4.5) years; 1199 relatives, mean age (SD) 10.1 (4.4) years). In total, 480 (25%) of all children had elevated Lp(a) concentrations (\u226530\u2005mg\/dL or \u226575\u2005nmol\/L). Both opportunistic (732 indexes) and systematic (316 indexes) cascade screening identified relatives with elevated Lp(a). The NNS was of 3.7 (95% CI 3.3\u20134.3) for the systematic approach and 4.1 (95% CI 3.8\u20134.6) for the opportunistic approach. In the FH subgroup, NNS were 3.9 (95% CI 3.4\u20134.5) and 4.3 (95% CI 3.9\u20134.8), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that cascade screening using children as index cases is an effective strategy to identify asymptomatic relatives at risk. Cardiovascular risk assessment should include Lp(a), especially in patients with FH who face an even higher cardiovascular risk. Until effective therapies become available, management should focus on modifiable risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag161","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T12:32:20Z","timestamp":1774182740000},"source":"Crossref","is-referenced-by-count":1,"title":["Cascade screening for elevated Lp(a) in relatives of children who visited the pediatric lipid clinic: yield of daily clinical practice"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9911-2456","authenticated-orcid":false,"given":"Sibbeliene E","family":"van den Bosch","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Gastroenterology Endocrinology Metabolism Research Institute , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences Research Institute , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotte M","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Gastroenterology Endocrinology Metabolism Research Institute , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences Research Institute , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia P T","family":"de Graaff","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W T","family":"Tanck","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willemijn E","family":"Corpeleijn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Gastroenterology Endocrinology Metabolism Research Institute , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-5671","authenticated-orcid":false,"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Gastroenterology Endocrinology Metabolism Research Institute , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9243-0037","authenticated-orcid":false,"given":"Barbara A","family":"Hutten","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Gastroenterology Endocrinology Metabolism Research Institute , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences Research Institute , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026040406051453900_zwag161-B1","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2026040406051453900_zwag161-B2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"2026040406051453900_zwag161-B3","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026040406051453900_zwag161-B4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S2213-8587(23)00156-0","article-title":"Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study","volume":"11","author":"De Boer","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026040406051453900_zwag161-B5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0021-9150(02)00003-5","article-title":"Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia","volume":"163","author":"De Jongh","year":"2002","journal-title":"Atherosclerosis"},{"key":"2026040406051453900_zwag161-B6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)15467-6","article-title":"Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia","volume":"363","author":"Wiegman","year":"2004","journal-title":"Lancet"},{"key":"2026040406051453900_zwag161-B7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCRESAHA.114.301430","article-title":"Carotid intima-media thickness in children with familial hypercholesterolemia","volume":"114","author":"Kusters","year":"2014","journal-title":"Circ Res"},{"key":"2026040406051453900_zwag161-B8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamapediatrics.2023.0763","article-title":"Cost-effectiveness and return on investment of a nationwide case-finding program for familial hypercholesterolemia in children in the Netherlands","volume":"177","author":"Ademi","year":"2023","journal-title":"JAMA Pediatr"},{"key":"2026040406051453900_zwag161-B9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/14656566.2022.2118522","article-title":"Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions","volume":"23","author":"De Boer","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2026040406051453900_zwag161-B10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026040406051453900_zwag161-B11","doi-asserted-by":"crossref","first-page":"100343","DOI":"10.1016\/j.ajpc.2022.100343","article-title":"Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a)","volume":"10","author":"Chakraborty","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"2026040406051453900_zwag161-B12","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jacl.2023.11.007","article-title":"Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial hypercholesterolaemia","volume":"18","author":"Loh","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026040406051453900_zwag161-B13","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/eurheartj\/ehac660","article-title":"Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study","volume":"44","author":"De Boer","year":"2023","journal-title":"Eur Heart J"},{"key":"2026040406051453900_zwag161-B14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacl.2023.03.010","article-title":"Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: a cross-sectional study","volume":"17","author":"De Boer","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2026040406051453900_zwag161-B15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13052-024-01732-8","article-title":"Is lipoprotein(a) measurement important for cardiovascular risk stratification in children and adolescents?","volume":"50","author":"Giussani","year":"2024","journal-title":"Ital J Pediatr"},{"key":"2026040406051453900_zwag161-B16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MOL.0000000000000951","article-title":"Effectiveness of cascade screening for elevated lipoprotein(a), an underdiagnosed family disorder","volume":"35","author":"Annink","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"2026040406051453900_zwag161-B17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamacardio.2023.3548","article-title":"Concordance of a high lipoprotein(a) concentration among relatives","volume":"8","author":"Reeskamp","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026040406051453900_zwag161-B18","doi-asserted-by":"crossref","first-page":"100940","DOI":"10.1016\/j.jacadv.2024.100940","article-title":"Lipoprotein(a) levels in disaggregated racial and ethnic subgroups across atherosclerotic cardiovascular disease risk levels","volume":"3","author":"Dudum","year":"2024","journal-title":"JACC Adv"},{"key":"2026040406051453900_zwag161-B19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"2026040406051453900_zwag161-B20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic","volume":"349","author":"De Boer","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026040406051453900_zwag161-B21","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf342","article-title":"Rationale for the routine screening of lipoprotein (a) in cardiovascular risk assessment","author":"Iatan","year":"2025","journal-title":"Eur J Prev Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag161\/67502081\/zwag161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag161\/67502081\/zwag161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:05:22Z","timestamp":1775297122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag161\/8539913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag161","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"article-number":"zwag161"}}